199 related articles for article (PubMed ID: 19026659)
1. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes.
Lapelosa M; Gallicchio E; Arnold GF; Arnold E; Levy RM
J Mol Biol; 2009 Jan; 385(2):675-91. PubMed ID: 19026659
[TBL] [Abstract][Full Text] [Related]
2. Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].
Lapelosa M; Arnold GF; Gallicchio E; Arnold E; Levy RM
J Mol Biol; 2010 Apr; 397(3):752-66. PubMed ID: 20138057
[TBL] [Abstract][Full Text] [Related]
3. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
[TBL] [Abstract][Full Text] [Related]
4. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.
Arnold GF; Velasco PK; Holmes AK; Wrin T; Geisler SC; Phung P; Tian Y; Resnick DA; Ma X; Mariano TM; Petropoulos CJ; Taylor JW; Katinger H; Arnold E
J Virol; 2009 May; 83(10):5087-100. PubMed ID: 19279101
[TBL] [Abstract][Full Text] [Related]
5. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.
Dong XN; Xiao Y; Chen YH
Immunol Lett; 2001 Jan; 75(2):149-52. PubMed ID: 11137140
[TBL] [Abstract][Full Text] [Related]
6. Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design.
Serrano S; Araujo A; Apellániz B; Bryson S; Carravilla P; de la Arada I; Huarte N; Rujas E; Pai EF; Arrondo JLR; Domene C; Jiménez MA; Nieva JL
J Biol Chem; 2014 Mar; 289(10):6565-6580. PubMed ID: 24429284
[TBL] [Abstract][Full Text] [Related]
7. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
Julien JP; Bryson S; Nieva JL; Pai EF
J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
[TBL] [Abstract][Full Text] [Related]
8. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
Guenaga J; Wyatt RT
PLoS Pathog; 2012; 8(7):e1002806. PubMed ID: 22829767
[TBL] [Abstract][Full Text] [Related]
10. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
[TBL] [Abstract][Full Text] [Related]
11. Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1.
Xiao Y; Dong X; Chen Y
Int Arch Allergy Immunol; 2000 Aug; 122(4):287-92. PubMed ID: 10971120
[TBL] [Abstract][Full Text] [Related]
12. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.
Zhai Y; Zhong Z; Zariffard M; Spear GT; Qiao L
Vaccine; 2013 Nov; 31(46):5422-9. PubMed ID: 24055348
[TBL] [Abstract][Full Text] [Related]
13. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.
Bryson S; Julien JP; Hynes RC; Pai EF
J Virol; 2009 Nov; 83(22):11862-75. PubMed ID: 19740978
[TBL] [Abstract][Full Text] [Related]
14. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
[TBL] [Abstract][Full Text] [Related]
15. Progress towards the development of a HIV-1 gp41-directed vaccine.
McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.
Ofek G; Zirkle B; Yang Y; Zhu Z; McKee K; Zhang B; Chuang GY; Georgiev IS; O'Dell S; Doria-Rose N; Mascola JR; Dimitrov DS; Kwong PD
J Virol; 2014 Mar; 88(5):2426-41. PubMed ID: 24335316
[TBL] [Abstract][Full Text] [Related]
17. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
Ofek G; Tang M; Sambor A; Katinger H; Mascola JR; Wyatt R; Kwong PD
J Virol; 2004 Oct; 78(19):10724-37. PubMed ID: 15367639
[TBL] [Abstract][Full Text] [Related]
18. Structural characterization of HIV gp41 with the membrane-proximal external region.
Shi W; Bohon J; Han DP; Habte H; Qin Y; Cho MW; Chance MR
J Biol Chem; 2010 Jul; 285(31):24290-8. PubMed ID: 20525690
[TBL] [Abstract][Full Text] [Related]
19. Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine.
Liao M; Lu Y; Xiao Y; Dierich MP; Chen Y
Peptides; 2000 Apr; 21(4):463-8. PubMed ID: 10822100
[TBL] [Abstract][Full Text] [Related]
20. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.
Tudor D; Yu H; Maupetit J; Drillet AS; Bouceba T; Schwartz-Cornil I; Lopalco L; Tuffery P; Bomsel M
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12680-5. PubMed ID: 22723360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
